Pain is a frequent symptom of atopic dermatitis (AD).
Objectives
The aims of the study were to evaluate the effects of dupilumab on pain/discomfort in AD and to determine whether pain correlates with other outcomes.
Methods
This was a post hoc analysis of 5 randomized, placebo-controlled clinical trials in which adults with chronic AD received placebo or dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids. Proportions of patients with no pain/discomfort on this dimension of the 5-dimension EuroQoL (EQ-5D) at week 16 (all trials) and week 52 (CHRONOS) were compared between placebo and dupilumab. Correlations were evaluated between pain/discomfort and signs and symptoms of AD.
Results
Among 2632 evaluated patients, 72.9% to 83.1% reported at least moderate pain/discomfort at baseline. Higher proportions treated with dupilumab reported no pain/discomfort at week 16 relative to placebo; risk differences ranged from 22.3% (95% confidence interval = 11.5%–33.1%) to 42.2% (95% confidence interval = 26.6%–57.8%, all P ≤ 0.0001), with similar effects observed at week 52. Correlations at baseline of pain/discomfort with signs and symptoms of AD were low to moderate.
Conclusions
Pain/discomfort, present in a substantial proportion of patients with moderate-to-severe AD, was significantly reduced by dupilumab treatment. Given the low-to-moderate correlations with other AD symptoms at baseline, pain likely represents a distinct AD symptom.
Trial Registration: ClinicalTrials.gov identifiers NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.
Get full access to this article
View all access options for this article.
References
1.
BoguniewiczM, LeungDY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev, 2011; 242(1):233–246.
2.
GittlerJK, ShemerA, Suarez-FarinasM, et al.Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol, 2012; 130(6):1344–1354.
3.
BrunnerPM, Suarez-FarinasM, HeH, et al.The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep, 2017; 7(1):8707.
4.
CzarnowickiT, KruegerJG, Guttman-YasskyE. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol, 2017; 139(6):1723–1734.
5.
WittkowskiA, RichardsHL, GriffithsCE, et al.Illness perception in individuals with atopic dermatitis. Psychol Health Med, 2007; 12(4):433–444.
6.
von KobyletzkiLB, ThomasKS, SchmittJ, et al.What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol, 2017; 97(1):86–90.
7.
SimpsonEL, BieberT, EckertL, et al.Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol, 2016; 74(3):491–498.
8.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol, 2018; 121(3):340–347.
9.
DruckerAM, WangAR, QureshiAA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association burden of disease audit. JAMA Dermatol, 2016; 152(8):873–874.
10.
VakhariaPP, ChopraR, SacotteR, et al.Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol, 2017; 119(6):548–552.e3.
11.
MaaroufM, KromenackerB, CapozzaKL, et al.Pain and itch are dual burdens in atopic dermatitis. Dermatitis, 2018; 29(5):278–281.
12.
SilverbergJI, SimpsonEL, de Bruin-WellerM, et al. Pain represents a distinct dimension of patient burden in patients with moderate-to-severe atopic dermatitis: a cross-sectional analysis of multiple phase 3 trials (LIBERTY AD SOLO 1 & 2 and CHRONOS). Poster presented at the 27th European Academy of Dermatology and Venereology Congress; September 12–16, 2018; Paris, France.
13.
FalissardB, SimpsonEL, Guttman-YasskyE, et al.Qualitative assessment of adult patients' perception of atopic dermatitis using natural language processing analysis in a cross-sectional study. Dermatol Ther (Heidelb), 2020; 10(2):297–305.
14.
KaazK, SzepietowskiJC, MatusiakL. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol, 2019; 99(2):175–180.
15.
SilverbergJI, GelfandJM, MargolisDJ, et al.Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract, 2019; 7(8):2699–2706.e7.
16.
AndersenHH, ElberlingJ, SolvstenH, et al.Nonhistaminergic and mechanical itch sensitization in atopic dermatitis. Pain, 2017; 158(9):1780–1791.
17.
WoolfCJ.Central sensitization: implications for the diagnosis and treatment of pain. Pain, 2011; 152(Suppl 3):S2–S15.
18.
ThaçiD, SimpsonEL, BeckLA, et al.Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo controlled, dose-ranging phase 2b trial. Lancet, 2016; 387(10013):40–52.
19.
SimpsonEL, BieberT, Guttman-YasskyE, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2016; 375(24):2335–2348.
20.
SimpsonEL.Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb), 2017; 7:243–248.
21.
SimpsonEL, GadkariA, WormM, et al.Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol, 2016; 75(3):506–515.
22.
de Bruin-WellerM, ThaçiD, SmithCH, et al.Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE). Br J Dermatol, 2017; 178(4):897–902.
23.
Le Floc'hA, AllinneJ, NagashimaK, et al.Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy, 2020; 75(5):1188–1204.
24.
BlauveltA, de Bruin-WellerM, GooderhamM, et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 2017; 389(10086):2287–2303.
25.
EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 1990; 16(3):199–208.
26.
SullivanPW, GhushchyanV. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making, 2006; 26(4):410–420.
27.
CharmanCR, VennAJ, WilliamsHC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol, 2004; 140(12):1513–1519.
28.
BasraMK, FenechR, GattRM, et al.The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol, 2008; 159(5):997–1035.
29.
ZigmondAS, SnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand Suppl, 1983; 67:361–370.
30.
CohenJ.A power primer. Psychol Bull, 1992; 112(1):155–159.
31.
VakhariaPP, ChopraR, SacotteR, et al.Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol, 2018; 178(4):925–930.
32.
ChalmersJR, SimpsonE, ApfelbacherCJ, et al.Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol, 2016; 175(1):69–79.
33.
SimpsonEL, Guttman-YasskyE, MargolisDJ, et al.Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol, 2018; 154(8):903–912.
34.
de Bruin-WellerM, GadkariA, AuziereS, et al.The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol, 2020; 34:1026–1036.
35.
McCarbergBH, NicholsonBD, ToddKH, et al.The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther, 2008; 15(4):312–320.
36.
RosenJD, FostiniAC, ChanYH, et al.Cross-sectional study of clinical distinctions between neuropathic and inflammatory pruritus. J Am Acad Dermatol, 2018; 79(6):1143–1144.
37.
AndersenHH, YosipovitchG, Arendt-NielsenL.Pain inhibits itch, but not in atopic dermatitis?. Ann Allergy Asthma Immunol, 2018; 120(5):548–549.
38.
GandhiNA, BennettBL, GrahamNM, et al.Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov, 2016; 15(1):35–50.
39.
HamiltonJD, Suarez-FarinasM, DhingraN, et al.Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol, 2014; 134(6):1293–1300.
40.
Guttman-YasskyE, BissonnetteR, UngarB, et al.Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol, 2019; 143(1):155–172.
41.
DavidsonS, GieslerGJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci, 2010; 33(12):550–558.
42.
LiuT, JiRR. New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?. Pflugers Arch, 2013; 465(12):1671–1685.
43.
LuoJ, FengJ, LiuS, et al.Molecular and cellular mechanisms that initiate pain and itch. Cell Mol Life Sci, 2015; 72(17):3201–3223.
44.
Busch-DienstfertigM, González-RodríguezS. IL-4, JAK-STAT signaling, and pain. JAKSTAT, 2013; 2(4):e27638.
45.
OetjenLK, MackMR, FengJ, et al.Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell, 2017; 171(1):217–228.e13.
46.
MiakeS, TsujiG, TakemuraM, et al.IL-4 augments IL-31/IL-31 receptor alpha interaction leading to enhanced Ccl 17 and Ccl 22 production in dendritic cells: implications for atopic dermatitis. Int J Mol Sci, 2019; 20(16):4053.
47.
IkomaA, FartaschM, HeyerG, et al.Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology, 2004; 62(2):212–217.
48.
HosogiM, SchmelzM, MiyachiY, et al.Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain, 2006; 126(1–3):16–23.
49.
AraiI, TsujiM, MiyagawaK, et al.Interleukin-31 (L-31) causes alloknesis: pain-stimulation becomes itch-stimulation in mouse skin. Itch Pain, 2015; 2:e924.
50.
TsujiM, AraiI, MiyagawaK, et al.Involvement of interleukin-31 receptor A in morphine-induced itching and antinociception in mice. Eur J Pain, 2019; 23(2):378–388.
